RNA Analytical/Quality Videos

  1. Analyzing COVID-19 Vaccine Purity Using LC-MS Technologies 11/8/2022

    Explore why process-related impurities are a concern in vaccines and present results and learnings from LC-MS analyses of several mRNA- and protein-based vaccines for COVID-19.

  2. The Challenges Novel Lipids Pose For mRNA-LNP Manufacturing 2/24/2026

    Though there are a lot of exciting advancements being made with novel lipid chemistries, CMC Consultant Sujit Jain provides an important reality check for us: These innovations break established platforms, requiring fresh process development, complex impurity profiling, and new vendor qualifications.

  3. Breaking New Ground: MHRA Embraces A Future With Patient-Specific mRNA 6/24/2025

    In this Advancing RNA clip, panelists Ulrike Jägle and Tiffany Lucas unpack the benefits they see to the MHRA's new guidance on mRNA cancer immunotherapies, including the agency’s support for bioinformatics approaches and its burgeoning framework for developing and justifying a truly personalized medicine.

  4. Validation Of mRNA Concentration Determination 8/20/2023

    mRNA-based therapeutics require comprehensive analytical testing to meet regulatory requirements. Optimize processes and ensure fast and reliable results as you bring your product to market.

  5. Bioinformatics In mRNA Development: Classification And Integration Conundrums 6/24/2025

    As both Advancing RNA Live speakers point out in this segment, the MHRA guidance focuses deeply on the critical role bioinformatics and AI/ML approaches will play in the development of personalized immunotherapies. Here, Eliquent Life Sciences’ Tiffany Lucas and CureVac’s Ulrike Jägle address the biggest challenges they anticipate companies will face in meeting the agencies’ recommendations.

  6. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

  7. Primates, Patents, And Progress: Advancements In Rational LNP Design 2/24/2026

    In this opening Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris share the scientific advancements they’ve been watching most keenly in the LNP space, as well as some of the evolutions they’re seeing in the overall quality of our RNA-LNP products.

  8. Closing the Gap: How NIST is Addressing gRNA Quality 4/29/2026

    Life Edit Therapeutics’ April Sena provides an update on NIST’s gene editing consortium, teasing forthcoming deliverables from a working group focused on gRNA quality. 

  9. Approving The World's First saRNA Vaccine: Arcturus' Regulatory Experience 5/10/2024

    Explore the behind-the-scenes best practices of the company implemented that led to the approval of the world’s first saRNA vaccine in Japan.

  10. RNA Interference - From Single Gene Studies To Whole Genome Screens 11/7/2022

    Endoribonuclease-prepared siRNAs (esiRNAs) are able to overcome the limitations of RNAi. Learn about esiRNAs, their advantages over standard siRNAs, and ways this technology is utilized in different research fields.